| Literature DB >> 28364132 |
Kathrin Ebner1, Claudia Dafinger1,2,3, Nadina Ortiz-Bruechle4, Friederike Koerber5, Bernhard Schermer2,3, Thomas Benzing2,3, Jörg Dötsch1, Klaus Zerres4, Lutz Thorsten Weber1, Bodo B Beck6, Max Christoph Liebau7,8,9.
Abstract
BACKGROUND: Autosomal recessive polycystic kidney disease (ARPKD) constitutes an important cause of pediatric end stage renal disease and is characterized by a broad phenotypic variability. The disease is caused by mutations in a single gene, Polycystic Kidney and Hepatic Disease 1 (PKHD1), which encodes a large transmembrane protein of poorly understood function called fibrocystin. Based on current knowledge of genotype-phenotype correlations in ARPKD, two truncating mutations are considered to result in a severe phenotype with peri- or neonatal mortality. Infants surviving the neonatal period are expected to carry at least one missense mutation. CASE-DIAGNOSIS/TREATMENT: We report on a female patient with two truncating PKHD1 mutations who survived the first 30 months of life without renal replacement therapy. Our patient carries not only a known stop mutation, c.8011C>T (p.Arg2671*), but also the previously reported c.51A>G PKHD1 sequence variant of unknown significance in exon 2. Using functional in vitro studies we have confirmed the pathogenic nature of c.51A>G, demonstrating activation of a new donor splice site in intron 2 that results in a frameshift mutation and generation of a premature stop codon.Entities:
Keywords: Autosomal recessive polycystic kidney disease; Congenital hepatic fibrosis; Fibrocystin; PKHD1; Polycystic kidney disease
Mesh:
Substances:
Year: 2017 PMID: 28364132 DOI: 10.1007/s00467-017-3648-x
Source DB: PubMed Journal: Pediatr Nephrol ISSN: 0931-041X Impact factor: 3.714